The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

M. Ducreux, G. K. Abou-Alfa, T. Bekaii-Saab, J. Berlin, A. Cervantes, T. de Baere, C. Eng, P. Galle, S. Gill, T. Gruenberger, K. Haustermans, A. Lamarca, P. Laurent-Puig, J. M. Llovet, F. Lordick, T. Macarulla, D. Mukherji, K. Muro, R. Obermannova, J. M. O'ConnorE. M. O'Reilly, P. Osterlund, P. Philip, G. Prager, E. Ruiz-Garcia, B. Sangro, T. Seufferlein, J. Tabernero, C. Verslype, H. Wasan, E. Van Cutsem

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    32 Citations (Scopus)

    Résumé

    This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

    langue originaleAnglais
    Numéro d'article101567
    journalESMO Open
    Volume8
    Numéro de publication3
    Les DOIs
    étatPublié - 1 juin 2023

    Contient cette citation